Skip to main content

150 publications

Name Date Type Actions

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

Public releases

2023 Half-Year Results

Contents
1.H1 2023 Highlights
2.H1 2023 Consolidatedfinancialstatements
3.Strategyand outlook

Half Year Report

Buyback programs - July

Monthly communication regarding buyback programs 
 

Description of buyback programs

Monthly information regarding the total number of voting rights - July 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Voting rights

Mastaplex and Vetoquinol announce distribution agreement

Mastaplex Ltd (New Zealand, unlisted) and Vetoquinol (VETO: France Euronext) are pleased to announce an extension of their exclusive distribution agreement for Mastatest..

Press releases communication

Update July 11, 2023 2023 CALENDAR OF FINANCIAL COMMUNICATION

Update July 11, 2023
Vetoquinol published its calendar of financial communication for 2023.

Agenda

Rapport financier semestriel 2022 (french)

Rapport financier semestriel 2022 (french)

Half Year Report

Growth driven by innovation

Ever since the company was founded in 1933, innovation has been a major component of Vetoquinol's development strategy.

Press releases communication

Rémunération et politique des dirigeants - mai 2023 (french)

Rémunération et politique des dirigeants
Résultats des votes de l’Assemblée Générale Mixte du 25 mai 2023

Shareholders´s Meeting

Vetoquinol - assemblée générale mixte - 25 mai 2023 : résultat du scrutin

Shareholders´s Meeting